The Bull Rankings scorecard — our quality-growth score is 79.5 / 100, built from three pillars scored 0–100: Quality 80, Growth 80, Value 79 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 12% next year, then recovering toward 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Covista’s current price of $119.45 sits on the cheap side of its sector peers, a fact our model flags with a Value score of 79. That softness is not a warning; it merely indicates the stock is already priced favorably. The real driver is the Quality pillar at 80. A high Quality score reflects solid profitability—profit margin 12.9%, ROE 17.4%, and a healthy free‑cash‑flow of $393 million—and a low debt‑to‑equity of 0.63 that keeps leverage in check. The Growth pillar, also at 80, shows a 9.3% revenue growth year‑over‑year, comfortably above the sector average for education services. Together, these pillars justify a bullish stance: Covista is a well‑managed, growing educator whose price already reflects modest upside.
What the business actually is
Covista operates three distinct education segments: Chamberlain, Walden, and Medical & Veterinary. Chamberlain University, the flagship, delivers bachelor’s, master’s, and doctoral degrees in nursing and allied health, plus online certificate programs for nursing, health professions, and medical fields. Walden University offers a broader portfolio—business, information technology, psychology, public health, social work, public administration, and criminal justice—while the Medical & Veterinary arm runs the American University of the Caribbean School of Medicine. The company’s revenue engine is a mix of tuition, licensing, and online course fees, with Chamberlain’s nursing programs driving the bulk of growth.
Why it can (or can't) keep compounding
Covista’s moat is two‑fold. First, its brand equity in nursing education is unmatched; Chamberlain is the largest U.S. nursing school, and its new Nashville campus signals aggressive geographic expansion. Second, the company’s online platform allows rapid scaling of certificate programs without the overhead of brick‑and‑mortar campuses. These advantages translate into a durable high return on capital—evidenced by a ROE of 17.4%—and a margin that has held steady at 12.9% despite industry headwinds. Competitors cannot replicate Chamberlain’s network of clinical partnerships or its established student pipeline without significant time and capital. The model’s “Buying back stock” signal further underscores management’s confidence in the business’s cash‑generating ability.
The valuation question
At a P/E of 15.9 and a PEG of 0.87, the market prices Covista with modest optimism. However, our reverse‑DCF analysis tells a different story: the current price implies a free‑cash‑flow growth of –12% in year 1, easing to 4% by year 10. This starting rate is below the trailing revenue growth of 9.3%, meaning the market has already priced in a pessimistic outlook on future cash‑flow expansion. If Covista can sustain its 9.3% revenue growth and maintain margins, the implied growth lag suggests a significant upside remains unpriced. The analyst consensus of $159.5 a year from now, coupled with a target range of $140–$175, indicates that many still see room for the stock to climb within the next 12–18 months.
The bear case
The most compelling risk is that Covista’s value pillar, while the softest, still sits at 79. A drop below this threshold—say, if the free‑cash‑flow margin were to slip below 12%—would erode the company’s cash‑generation profile and strain its debt‑to‑equity ratio. A concrete trigger would be a revenue growth dip below 9% or a margin contraction below 12%, both of which would undermine the model’s Quality score and push the stock toward a less attractive valuation.
What would change our mind
- Revenue growth falling under 9% in the next quarter would signal a slowdown in the nursing and online certificate pipeline, weakening the Growth pillar.
- Profit margin slipping below 12.9% would erode the company’s profitability cushion and lower the Quality score.
- Debt‑to‑equity rising above 0.63 would increase leverage risk, pulling the Value pillar down and making the stock less defensible.
If any of these thresholds were breached, the current bullish thesis would need reevaluation.